Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy by Miyata Yasuyoshi et al.
Pathological Signif|cance and Prognostic Role ofMicrovessel
Density,EvaluatedUsingCD31,CD34, andCD105 in
ProstateCancer PatientsAfter Radical Prostatectomy
WithNeoadjuvant Therapy
Yasuyoshi Miyata,* Kensuke Mitsunari, Akihiro Asai, Kosuke Takehara, Yasushi Mochizuki,
and Hideki Sakai
DepartmentofUrology,NagasakiUniversityGraduate Schoolof Biomedical Sciences,Nagasaki, Japan
BACKGROUND. Neoadjuvant hormonal therapy (NHT) is performed to improve the
outcome in organ-confined prostate cancer. However, there is little information regarding
the relationship between angiogenesis and NHT. The aim of this study was to identify a
suitable method to evaluate the angiogenic status of tissue, and to determine the prognostic
value of this method for biochemical recurrence in patients who had undergone radical
prostatectomy after NHT.
METHODS. We analyzed 108 formalin-fixed specimens from patients treated by radical
prostatectomy. NHT was administered in 48 patients (52.9%) and 60 patients who had a
similar Gleason score and pT stage were selected as a non-NHT treated control group.
Microvessel density (MVD) was measured using anti-CD31, anti-CD34, and anti-CD105
antibodies. The expressions of vascular endothelial growth factor (VEGF)-A and thrombospon-
din (TSP)-1 were also evaluated by immunohistochemistry. The prognostic value of CD31-,
CD34-, and CD105-MVD for biochemical recurrence was investigated.
RESULTS. The mean/SD of CD105-MVD in the NHT group (13.3/4.7) was significantly
(P< 0.001) lower than that in the non-NHT group (125.8/7.3). In the NHT group, CD105-MVD
was associated with pT stage and it was positively correlated with VEGF-A expression
(r¼ 0.56, P< 0.001) and negatively correlated with TSP-1 expression (r¼ 0.42, P¼ 0.003).
CD105-MVD was identified as a significant predictor of biochemical recurrence (BCR) in
patients treated with NHT (log rank test, P< 0.001). Although CD31- and CD34-MVD were
significantly associated with pT stage or Gleason score in non-NHT group, they were not
associated with pathological features and BCR in NHT group.
CONCLUSIONS. Our results indicate that CD105-MVD reflects the angiogenic conditions in
prostate cancer tissues treated with NHT. CD105-MVD was also identified as a significant and
independent predictor of biochemical recurrence in prostate cancer patients who underwent
radical prostatectomy with NHT. Prostate 75: 84–91, 2015.
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INTRODUCTION
Neoadjuvant hormonal therapy (NHT) is often
performed to decrease the number of residual cancer
cells and to improve the outcome of patients with
organ-confined prostate cancer; a third of all patients
who receive radical treatment subsequently experience
recurrence and metastasis, even in patients with
organ-confined disease [1]. However, the anti-tumor
effects of NHT, including improvement in patient
outcome, are far from satisfactory. In recent years,
various anti-angiogenic agents have been reported to
be effective in many different types of malignancy. As
such, detailed information regarding the pathological
role of angiogenesis, and the mechanisms that regulate
it, are important in choosing the most appropriate
strategies of observation and treatment. The impact
that NHT exerts on angiogenesis and the expression of
angiogenesis-related molecules is not fully under-
stood.
To understand the pathological significance and
prognostic value of angiogenesis in malignancies,
effective methods for determining cancer-related neo-
vascularity in malignancies are essential. In human
cancer tissues, the most common method for semi-
quantitative evaluation of angiogenesis is to measure
microvessel density (MVD) using endothelial markers.
MVD has been widely used for the evaluation of
angiogenesis in many previous studies, and it is
recognized as one of the most useful prognostic
markers for tumor progression and survival in patients
with various different types of cancer. Immunohis-
tochemistry and antibodies against the endothelial cell
markers CD31, CD34, and CD105 have frequently
been used in previous studies of cancer tissues. There
are many reports that have used these antibodies to
investigate the pathological significance of MVD in
prostate cancer tissues [2–4]. However, there is rela-
tively little published literature regarding whether this
semi-quantitative method has any pathological signifi-
cance in prostate cancer patients treated with NHT; if
such a relationship were established, then it is possible
that it can be applied to determining the prognosis of
prostate cancer patients treated with NHT.
There is general agreement that various factors
regulate angiogenesis in prostate cancer. The roles of
the pro-angiogenic vascular endothelial growth factor
(VEGF)-A and the anti-angiogenic thrombospondin
(TSP)-1 have been well characterized in various differ-
ent malignancies. Interestingly, androgen is a potent
stimulator of VEGF-A expression [5,6] and a suppres-
sor of TSP-1 activity in prostate cancer [7]. Actually,
androgen depletion has been reported to increase
VEGF-A expression and decrease TSP-1 expression in
prostate cancer [7–9]. Thus, various studies support
the view that androgen plays an important role in
angiogenic processes in prostate cancer; however, the
relationship between NHT and angiogenic activities,
including MVD, and the expression of angiogenesis-
related factors in human prostate cancer tissues are not
fully understood.
In this study, we investigated endothelium markers
that can be used to reflect the pathological role and
clinical significance of angiogenesis in prostate cancer
patients treated with NHT prior to radical operation.
In order to evaluate cancer-related neovascularity, we
also compared the expression of VEGF-A and TSP-1 in
prostate cancer specimens from patients who were or
were not treated with NHT. Finally, we investigated
and discussed the predictive value of MVD for




Included in the study were specimens from
108 prostate cancer patients that had undergone a
radical prostatectomy (RP) at our hospital. Among
them, 48 patients (44.4%) received NHT (NHT group)
and 60 patients (55.6%) were not treated with NHT
(non-NHT group). In this study, patients who were
treated with NHT for <3 months, had clinical or
pathological invasion into the seminal vesicle or
surrounding tissues, underwent metastasis, had a
Gleason score (GS) of 10, or serum prostate antigen
(PSA) levels >90 ng/ml were excluded. In order to
match the clinicopathological features of the non-NHT
and NHT groups, patient’s age, PSA levels, GS, and
pT stage were collected. In addition, specimens with
<300 cancer cells/specimen or with very few or no
viable cancer cells were also excluded.
All patients were evaluated using chest radiogra-
phy, transrectal ultrasonography, bone scanning, and
computed tomography (CT) of the pelvis and abdo-
men. In addition, CT of the lungs and magnetic
resonance imaging of the prostate or bone was
performed when necessary. A patient’s disease stage
was assessed using the 2002 tumor-node-metastasis
(TNM) staging system and GS. NHT consisted of anti-
androgen agent (n¼ 1, 2.1%), luteinizing hormone-
releasing hormone (LH-RH) agonists (n¼ 20, 41.7%),
or a combined androgen blockage therapy consisting
of LH-RH agonists and anti-androgen agent (n¼ 27,
56.3%). The median duration of NHT was 8 months
(interquartile range 5–11 months). BCR was defined as
serum PSA levels that were >0.2 ng/ml, as measured
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on two or more occasions. The study protocol was
approved by the Human Ethics Review Committee of
Nagasaki University Graduate School of Biomedical
Science, and a signed consent form was obtained from
each subject.
Immunohistochemistry
Sections were cut 5mm thick, deparaffinized in
xylene, and rehydrated in solutions of graded ethanol.
Antigen retrieval was performed at 95°C for 40min in
0.01M sodium citrate buffer (pH 6.0). Sections were
then immersed in 3% hydrogen peroxide for 30min to
block endogenous peroxidase activity. Primary anti-
bodies were obtained from Novocastra (New Castle,
United Kingdom; anti-human CD31 antibody), Dako-
Cytomation (Glostrup, Denmark; anti-human CD34
antibody), Vector Laboratories (Burlingame, CA; anti-
human CD105 antibody), Santa Cruz Biotechnology
(Santa Cruz, CA; anti-VEGF-A antibody), and (Cam-
bridge, UK; anti-TSP-1 antibody). Sections were incu-
bated with primary antibodies at 4°C overnight.
Following primary antibody incubation, sections were
treated using the labeled polymer peroxidase method
(DAKO EnVisionTMþ Peroxidase Kit, Dako, Carpinte-
ria, CA) for 60min. Proteins were visualized using a
liquid diaminobenzidine substrate kit (Zymed Labora-
tories, San Francisco, CA). Sections were counter-
stained with hematoxylin before mounting. Negative
controls consisted of adjacent sections from each
sample that were processed without the primary
antibody. The positive control for all antibodies was
kidney tissue, including renal cell carcinoma. The
immunohistochemical staining methods used for all of
the antibodies have previously been described [10,11].
The analysis of immunohistochemical staining
within the tumor area of sections was performed using
a light microscope. The expression levels of VEGF-A
and TSP-1 were semi-quantitatively assessed using a
method similar to that previously described [12].
Briefly, VEGF-A staining was scored as 0 (negative), 1
(weak), 2 (moderate), or 3 (strong) according to the
staining intensity. In addition, the extent of staining
was scored as 0 (nothing), 1 (1–25%), 2 (26–50%), 3
(51–75%), or 4 (76–100%) according to the percentage
of the positively stained cancer cells [12]. TSP-1
expression was scored as 0 (negative), 1 (weak), 2
(moderate), or 3 (strong) depending on the staining
intensity in the cancer region [7]. The extent of TSP-1
expression was not scored because it is difficult to
evaluate the stained area in stromal tissues. The semi-
quantitative analysis and immunostaining interpreta-
tion was independently performed by two investiga-
tors (S.W. and Y.M.) who were blinded to clinical
features and survival data.
To determine the MVD, tumor sections stained with
each antibody were examined using a Nikon E-400
bright-field microscope (Nikon, Tokyo, Japan). Images
were captured using a digital camera (DU100; Nikon)
and a 200 magnification objective lens. For each
tumor section, 3–5 hot spot fields of view (that had the
greatest density of positively stained vessels) were
evaluated. MVD was defined as the number of
positively stained vessels per high-power field of view
(HPF), estimated using computer-aided image analysis
(WinROOF version 6.4; Mitani, Fukui, Japan). For
statistical analysis, each MVD was divided into two
groups: low (median or less) and high (greater than
the median).
StatisticalMethods
Normality was evaluated by normal distribution.
Histograms were prepared for each variable and the
results are expressed as the mean and standard
deviation (SD). The Student’s t-test was performed for
continuous variables. The Mann–Whitney U test was
also used for some data. The Scheffe test was used for
multiple comparisons of data. Pearson’s correlation
and the correlation coefficient (r) were used to evaluate
the relationship between continuous variables, and the
corresponding P values are shown. Spearman’s rank
correlation coefficient was calculated to confirm the
Pearson’s correlation results. In survival analyses, the
Kaplan–Meier survival curve and log-rank test were
used, and Cox proportional hazards model multivari-
ate analysis was also performed. All statistical tests
were two-sided, and significance was defined as
P< 0.05. All statistical analysis was performed on a
personal computer using the StatView for Windows
statistical package (version 5.0; Abacus Concepts, CA).
RESULTS
The age of the patients ranged from 51 to 71 years
(median 64 years); there was no significant difference
in age between the non-NHT and NHT groups
(P¼ 0.082). There were also no significant differences
between the non-NHT and NHT groups in regard to
serum PSA levels at diagnosis (mean 12.3/SD 9.3 and
15.1/SD 10.8 ng/ml, respectively, P¼ 0.166) or in
regard to the pathological diagnosis. There were 17
(28.3%), 25 (41.7%), and 18 (30.0%) non-NHT group
patients and 8 (16.7%), 29 (60.4%), and 11 (22.9%) NHT
group patients judged as having low, middle, and
high GSs, respectively. In the non-NHT group, pT2
and pT3 disease was observed in 36 (60.0%) and 24
(40.0%) patients, respectively; in the NHT group, pT2
and pT3 disease was observed in 31 (64.6%) and 17
(35.4%) patients, respectively. Thus, no significant
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differences in pT stage were observed between the
groups (P¼ 0.626).
CD31,CD34, andCD105 staining
Representative examples of CD31, CD34, and
CD105 positively stained vessels in prostate cancer
tissues with NHT are shown in Figure 1A–C, respec-
tively. In addition, CD31, CD34, and CD105 vessel
staining in low GS prostate cancer tissues with non-
NHT are shown in Figure 1D–F, respectively. Similar
vessels in high GS non-NHT tumors are shown in
Figure 1G–I. Many CD34 positively stained vessels
were clearly detected in the degenerate area of cancer
tissues with NHT (Fig. 1B). However, CD105 positively
stained vessels were rare in similar areas (Fig. 1C).
In low GS non-NHT specimens, CD105 positively
stained vessels were rare. We also noted that the
endothelial cells of large and mature blood vessels
were strongly stained by the anti-CD31 and anti-CD34
antibodies, but not by the anti-CD105 antibody
(arrows in Fig. 1D–F). In contrast to the low GS tissue,
CD105 positively stained vessels were clearly detected
in high GS prostate cancer tissue (Fig. 1I).
The mean (SD) CD31-, CD34-, and CD105-MVD/
HPF in the non-NHT specimens were 38.6 (7.9), 50.2
(9.1), and 25.8 (7.3), respectively. The mean (SD) CD31-,
CD34-, and CD105-MVD/HPF in the NHT specimens
were 36.5 (9.1), 50.1 (7.4), and 13.3 (4.7), respectively.
Although the CD31-, CD34-, and CD105-MVD in the
Fig. 1. (A^C) Representative examples of CD31,CD34, and CD105 stained vessels in prostate cancer tissues that were not treatedwith
neoadjuvant therapy (NHT), respectively. Indegenerated tissues,CD31andCD34positivevesselswererelatively abundant, butCD105 stain-
ing was weak in similar areas. (D^F ) CD31,CD34, and CD105 stained vessels in low Gleason’s score (GS) non-NHT tissues, respectively.
The number ofCD105 positivevessels in the tumor areawas clearly lower than the number ofCD34 positivevessels.The endothelial cells of
large and mature blood vessels were strongly stained for CD31and CD34, but not for CD105 (arrows in D^F ). (G^I) CD31, CD34, and
CD105 stainedvessels in highGSnon-NHT tissues, respectively. In contrast to lowGS tissue,CD105 positivevesselswere clearlydetected in
highGSprostate cancer (I). In almostof all of the specimens, the intensity andnumber ofCD31positively stainedvesselswerewith therange
of thenumberofCD105andCD34positively stainedvessels.
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NHT group (Fig. 2A–C) tended to be lower than in the
non-NHT group, only CD105-MVD was significantly
different (P< 0.001). As shown in Figure 2D and E, a
similar difference in VEGF-A and TSP-1 expression
between the non-NHTand NHT group was also found.
Correlationof VEGF-AandTSP-1Expressionwith
Pathological Features
In the NHT group specimens, CD105-MVD posi-
tively correlated with VEGF-A expression (r¼ 0.56,
P< 0.001) while TSP-1 expression negatively correlat-
ed with CD105-MVD (r¼ 0.42, P¼ 0.003). CD31-MVD
was not correlated with VEGF-A (r¼ 0.21, P¼ 0.149)
or TSP-1 (r¼ 0.03, P¼ 0.845) expression in the NHT
group samples. Similarly, CD34-MVD was not corre-
lated with VEGF-A (r¼ 0.11, P¼ 0.472) or TSP-1
(r¼ 0.14, P¼ 0.358) expression in the NHT group.
The relationship between CD31- CD34- and CD105-
MVD and the patient’s pathological features are
showed in Table I. In the non-NHT patients, the CD31-,
CD34-, and CD105-MVD were significantly correlated
with GS and pT stage. However, in the NHT
patients, there was no correlation between CD31- and
CD34-MVD and a patient’s pathological features.
However, CD105-MVD in the NHT patients was
significantly correlated with their pT stage, but not
with their GS.
PredictiveValue for BCR
We analyzed the prognostic value of CD31-, CD34-,
and CD105-MVD for BCR after RP in NHT treated
patients (Fig. 3A–C). Kaplan–Meier survival curves
indicated that CD105-MVD was significantly associat-
ed with BCR in patients treated with NHT. However,
CD31- and CD34-MVD were not significant predictors
in this analysis. Univariate Cox regression analysis
indicated that the clinicopathological risk factors GS,
pT stage, and serum PSA levels at diagnosis were not
associated with BCR in the NHT group patients. As
such, only CD105-MVD can be used as a predictive
factor for BCR (Table II). This was shown by both
univariate and multivariate analyses.
DISCUSSION
Our results indicate that CD31-, CD34-, and CD105-
MVD are positively associated with GS and pT stage
in non-NHT group. These results are similar to those
of previous studies, which have investigated the
relationship between MVD and pathological features
in RP specimens from non-NHT treated patients [2,3].
Fig. 2. Microvesseldensities (MVD) innon-neoadjuvant therapy
(non-NHT) and NHT group were showed. Among 3 MVDs,
CD105-MVDinNHTwas significantly lower than that in non-NHT.
Such significant difference was not found in CD31- and CD34-
MVD.
TABLEI. CorrelationWith Pathological Features
Mean MVD (SD) in non-NHT Mean MVD (SD) in NHT
N CD31 CD34 CD105 N CD31 CD34 CD105
GS
Low 17 34.1 (7.3) 44.5 (8.0) 22.0 (6.8) 8 31.5 (7.5) 48.8 (9.2) 13.7 (5.3)
Middle 25 39.7 (8.0) 51.7 (8.5) 26.0 (5.5) 29 37.9 (9.4) 51.5 (6.7) 12.9 (4.3)
High 18 41.3 (7.0) 53.3 (8.7) 28.9 (8.7) 11 36.1 (8.6) 47.4 (7.4) 14.2 (5.5)
P value† 0.023 0.001 0.019 NS NS NS
P value‡ 0.035/0.032 0.038/0.038 0.005/0.007 0.894/0.874 0.238/0.137 0.502/0.428
T stage
pT2 36 35.9 (5.5) 45.9 (6.4) 22.8 (6.0) 31 34.7 (9.0) 48.8 (7.3) 12.0 (4.7)
pT3 24 42.6 (9.4) 56.5 (8.8) 30.4 (6.8) 17 39.7 (8.7) 52.5 (7.0) 15.7 (3.8)
P value 0.001/0.001 <0.001/<0.001 <0.001/<0.001 0.065/0.091 0.092/0.077 0.008/0.012
MVD, microvessel density; NHT, neoadjuvant hormonal therapy; GS, Gleason’s score; NS, not significant; SD, standard deviation.
†Low versus High, using multiple comparison tests.
‡Low and Middle versus High, respectively, using Student’s t-test/Mann–Whitney U test.
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However, there is little information regarding the
pathological significance and prognostic value of
MVD in prostate cancer patients treated with RP
following NHT treatment. The present study demon-
strates that CD105-MVD is positively correlated with
pT stage in NHT group; however, CD31- and CD34-
MVD showed no such correlation. Thus, our results
suggest that the vascular endothelial cells detected by
the anti-CD105 antibody in prostate cancer tissues
from NHT treated patients have different pathological
characteristics from those detected by the anti-CD31
and anti-CD34 antibodies. Indeed, although CD31 and
CD34 are known as pan-endothelial markers, which
stain almost all blood vessels, including mature and
newly formed blood vessels, CD105 is recognized as a
proliferation-associated endothelial marker, which is
induced by hypoxia. CD105 is, therefore preferentially
expressed in the active dividing endothelial cells of
microvessel in cancer tissues [13]. Indeed, our results
indicated that large and established mature blood
vessels did not stain positive for CD105, even though
they clearly stained positive for CD31 and CD34.
Furthermore, several other studies support the opinion
that CD105-MVD may more precisely reflect the
tissues angiogenic status of a variety of different
cancer tissues than either CD31- or CD34-MVD
[10,14,15].
Apart from measuring MVD, many investigators
have studied the expression levels of angiogenesis-
related molecules, such as VEGF-A and TSP-1, to
evaluate the angiogenic activities of human tissues.
Androgen deprivation has been reported to inhibit
VEGF-A expression in prostate cancer patients [12],
and similar results were also found in an in vivo study
using a hormone-sensitive prostate cancer cell line [9].
However, TSP-1 expression is reported to increase
following hormonal therapy in both hormone-sensi-
tive prostate cancer tissues and mouse models [7,16].
Our results support the notion that NHT stimulates
anti-angiogenic activity in prostate cancer tissues; the
CD105-MVD of NHT treated prostate cancer tissues
was significantly lower than that of non-NHT treated
Fig. 3. Kaplan^Meier survival curves showed thatpatientswith
highCD105-MVDhaveworseprognosis of biochemical recurrence
(BCR) compared to those with low one (log rank P¼ 0.001). On
the other hand,CD31- and CD105-MVDwere not associatedwith
BCR.
TABLEII. PredictiveValue for Biochemical Recurrence in theNeoadjuvant Group
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Serum PSA level at diagnosis 1.02 0.98–1.05 0.396 1.01 0.96–1.06 0.648
High Gleason score (8) 2.28 0.56–9.30 0.250 1.23 0.46–3.26 0.684
High pT stage (pT3) 1.86 0.80–4.34 0.149 0.87 0.30–2.54 0.802
High CD105-MVD (>20/HPF) 4.68 1.83–12.02 0.001 4.45 1.61–12.26 0.004
HR, hazard ratio; CI, confidential interval; PSA, prostate-specific antigen; MVD, microvessel density.
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patients. On the other hand, there was no significant
difference in CD31- or CD34-MVD between the NHT
and non-NHT prostate cancer tissues. It has previously
been reported that in NHT and non-NHT treated
human prostate cancer specimens, CD31-MVD does
not significantly differ [17]. Furthermore, several stud-
ies using animal models have also shown that andro-
gen deprivation does not reduced CD31-MVD in
cancer tissues [18,19]. There is also a report that
indicates that the CD34-MVD in prostate cancer
tissues at the time of diagnosis does not significantly
reduce following androgen deprivation therapy [20].
From these facts, we speculate that CD31- and CD34-
MVD do not accurately reflect changes in the angio-
genic status stimulated by hormonal therapy in pros-
tate cancer patients. We conclude that an anti-CD105
antibody may detect newly formed cancer-related
blood vessels more accurately than anti-CD31 or anti-
CD34 antibodies in prostate cancer specimens treated
with hormonal therapy.
Another interesting result from the present study is
that CD105-MVD in RP specimens from patients
treated with NHT is a significant predictive factor for
BCR. There is some concern that the pathological
features following hormonal therapy do not always
reflect the malignant potential and aggressiveness of a
tumor because androgen deprivation may lead to
morphological changes and deformities of the cancer
cell. As such, NHT can make it difficult to produce an
accurate pathological diagnosis, including the GS and
pT stage. Furthermore, these morphological effects
exerted by hormonal therapy may affect the outcome
of prostate cancer patients treated with NHT. As such,
predicting the prognosis of patients who undergo RP
following NHT treatment may be more difficult to
judge than for non-NHT treated patients. Indeed, our
study indicated that GS and pT stage were not useful
predictive factors for BCR in the NHT group, and
similar results have previously been published [21].
Thus, more information regarding appropriate predic-
tive factors for patient prognosis is important in
discussing the efficacy and limitations of NHT for
organ-confined prostate cancer. The present study has
demonstrated that BCR in patients treated with NHT
was significantly and independently associated with
CD105-MVD, but not with CD31- or CD34-MVD. This
might be a consequence of the relationship between
the specific marker and the patient’s pathological
features, VEGF-A expression, or TSP-1 expression.
CONCLUSIONS
Our results show that CD105-MVD may more
accurately reflect the angiogenic conditions and malig-
nant potential of prostate cancer tissues than CD31-
MVD or CD34-MVD. High CD105-MVD was also
correlated with high VEGF-A expression and low TSP-1
expression in NHT treated patients. Furthermore,
CD105-MVD was identified as a significant indepen-
dent predictor of BCR in prostate cancer patients who
had undergone RP following NHT treatment.
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